What is the starting dose of Atarax (hydroxyzine) for an adult patient with anxiety?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hydroxyzine Starting Dose for Anxiety in Adults

The FDA-approved starting dose of hydroxyzine (Atarax) for anxiety in adults is 50-100 mg four times daily (q.i.d.), though clinical practice often begins at 50 mg daily in divided doses and titrates based on response. 1

Standard Adult Dosing

  • The FDA label specifies 50-100 mg four times daily for symptomatic relief of anxiety and tension associated with psychoneurosis. 1
  • Clinical trials have consistently used a fixed dose of 50 mg daily (typically divided as 25 mg twice daily or in other divided doses) with demonstrated efficacy superior to placebo from the first week of treatment. 2
  • A study of 55 patients with generalized anxiety and somatoform disorders used 50 mg daily for 28 days with good tolerability and significant anxiety reduction. 3

Practical Dosing Strategy

  • Start with 50 mg daily in divided doses (e.g., 25 mg twice daily) rather than the full FDA-labeled dose of 50-100 mg q.i.d., as this lower starting approach has proven effective in clinical trials and reduces initial sedation. 3, 2
  • Assess response after 1 week of scheduled dosing, as PRN (as-needed) use is less optimal for titration purposes. 4
  • The dose should be adjusted according to the patient's response to therapy, as emphasized in the FDA labeling. 1
  • Efficacy is maintained throughout 4 weeks of treatment with early improvement in cognitive components of anxiety. 2

Special Population Considerations

Elderly Patients

  • Reduce the starting dose to 25 mg three to four times daily (approximately 25-50% of standard adult dose) in elderly patients, titrating cautiously and slowly based on individual response. 4
  • Elderly patients have increased risk of falls, cognitive impairment, and paradoxical agitation with sedating medications. 5

Important Safety Considerations

  • The most common side effect is sedation/drowsiness, occurring in approximately 36% of patients, which is typically transitory. 6
  • Other side effects include weakness (18%), headache (6%), and mild dry mouth (2%). 6
  • Hydroxyzine lacks organ toxicity and has no dependency potential, distinguishing it from benzodiazepines. 2
  • Address reversible causes of anxiety first before initiating pharmacological treatment, including exploring patient concerns and treating underlying medical conditions. 4, 7

Comparative Context

  • While hydroxyzine 50 mg daily shows efficacy comparable to benzodiazepines (lorazepam, chlordiazepoxide) and buspirone, it demonstrates greater and more rapid cognitive improvement compared to lorazepam. 8, 2, 9
  • However, current guidelines favor SSRIs/SNRIs as first-line for chronic anxiety disorders in most populations, with better evidence for long-term use. 4
  • Benzodiazepines like lorazepam 0.25-0.5 mg are recommended by NICE as first-line for acute anxiety, particularly in elderly patients. 4

References

Research

Recent clinical trials of hydroxyzine in generalized anxiety disorder.

Acta psychiatrica Scandinavica. Supplementum, 1998

Guideline

Geriatric Anxiety Treatment with Hydroxyzine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diazepam Dosage and Administration for Anxiety Attacks

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Atarax in treatment of anxiety in outpatient clinic].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1998

Guideline

Lorazepam Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Hydroxyzine for generalised anxiety disorder.

The Cochrane database of systematic reviews, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.